脂蛋白(a)水平与冠心病患者易损斑块独立相关
作者:
作者单位:

(新疆医科大学第一附属医院心脏中心冠心病科,新疆乌鲁木齐市 830011)

作者简介:

王钧,硕士研究生,研究方向为冠心病基础及介入治疗,E-mail为1057958292@qq.com。通信作者杨毅宁,主任医师,教授,博士研究生导师,主要研究方向为冠心病基础及介入治疗,E-mail为yangyn5126@163.com。

基金项目:

新疆维吾尔自治区科技支疆项目(2016E02072);重大慢性非传染性疾病防控研究项目(2018YFC1312804)


Lipoprotein(a) level is independently correlated with vulnerable plaques in patients with coronary heart disease
Author:
Affiliation:

(Department of Coronary Heart Disease, the First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang 830011, China)

  • 摘要
  • | |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
    摘要:

    目的 基于光学相干断层成像技术(OCT)研究脂蛋白(a)水平与冠状动脉易损斑块之间的相关性。方法 入选2015年1月至2018年8月在新疆医科大学第一附属医院心脏中心住院并经冠状动脉造影确诊为冠心病的患者,进行光学相干断层成像(OCT)检查。应用多重线性回归等统计方法分析脂蛋白(a)水平与冠状动脉易损斑块之间的关系。结果 共入选144例患者。(1)根据脂蛋白(a)水平将患者分为脂蛋白(a)≤300 mg/L组(n=99)和脂蛋白(a)>300 mg/L组(n=45);脂蛋白(a)>300 mg/L组斑块脂质弧比脂蛋白(a)≤300 mg/L组大(P=0.021),易损斑块发生率比脂蛋白(a)≤300 mg/L组高(P=0.001)。(2)利用OCT将患者分为易损斑块组(n=36)和非易损斑块组(n=108),2组之间性别、吸烟史、2型糖尿病、体质指数、低密度脂蛋白、脂蛋白(a)差异均有统计学意义(均P<0.05);多因素Logistic回归分析显示,脂蛋白(a)、2型糖尿病、低密度脂蛋白为易损斑块的独立影响因素,是易损斑块发生的预测因子。结论 高水平脂蛋白(a)与冠状动脉易损斑块独立相关。

    Abstract:

    Aim To study the correlation between lipoprotein(a) [Lp(a)] level and coronary vulnerable plaque based on optical coherence tomography (OCT). Methods From January 2015 to August 2018, patients admitted to the Heart Center of the First Affiliated Hospital of Xinjiang Medical University who were diagnosed as coronary heart disease by coronary angiography were examined by OCT. The analysis of the relationship between lipoprotein (a) level and coronary vulnerable plaque were completed by multiple linear regression and other statistical methods. Results A total of 144 patients were enrolled. (1)According to the Lp(a) level, the patients were divided into two groups:Lp(a) ≤300 mg/L group (n=99) and Lp(a) >300 mg/L group (n=45). The lipid arc of plaque in Lp(a) >300 mg/L group was larger than that in Lp(a) ≤300 mg/L group (P=0.021), and the incidence of vulnerable plaque was higher than that in Lp(a) ≤300 mg/L group (P=0.001). (2)The patients were divided into vulnerable plaque group (n=36) and non-vulnerable plaque group (n=108) by OCT. There were significant differences in sex, smoking history, type 2 diabetes mellitus, body mass index, low density lipoprotein and Lp(a) between the two groups (all P<0.05). Multivariate Logistic regression analysis showed that Lp(a), type 2 diabetes mellitus and low density lipoprotein were independent influencing factors of vulnerable plaque, and were predictors of vulnerable plaque occurrence. Conclusion The high level of lipoprotein (a) is independently correlated with coronary vulnerable plaques.

    参考文献
    [1] 马丽媛, 吴亚哲, 王文, 等.《中国心血管病报告2017》要点解读.中国心血管杂志, 8,3(1):3-6.
    [2] Khot UN, Khot MB, Bajzer CT, et al.Prevalence of conventional risk factors in patients with coronary heart disease.JAMA, 3,0(7):898-904.
    [3] Greenland P, Knoll MD, Stamler J, et al.Major risk factors as antecedents of fatal and nonfatal coronary heart disease events.JAMA, 3,0(7):891-897.
    [4] Khera AV, Everett BM, Caulfield MP, et al.Lipo-protein(a) concentrations, rosuvastatin therapy, and residual vascular risk:analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention:an Intervention Trial Evaluating Rosuvastatin).Circulation, 4,9(6):635-642.
    [5] Zhao Y, Delaney JA, Quek RGW, et al.Cardiovascular disease, mortality risk, and healthcare costs by lipoprotein(a) levels according to low-density lipoprotein cholesterol levels in older high-risk adults.Clin Cardiol, 6,9(7):413-420.
    [6] Dai W, Long J, Cheng Y, et al.Elevated plasma lipoprotein(a) levels were associated with increased risk of cardiovascular events in Chinese patients with stable coronary artery disease.Sci Rep, 8,8(1):7726.
    [7] Hoefler G, Harnoncourt F, Paschke E, et al.Lipoprotein(a):A risk factor for myocardial infarction.Arteriosclerosis, 8,8(4):398-401.
    [8] Anderson TJ, Grégoire J, Pearson GJ, et al.2016 Canadian cardiovascular society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult.Can J Cardiol, 6,2(11):1263-1282.
    [9] Jang IK, Teamey GJ, MacNeill B, et al.In vivo characterization of coronary atherosclerotic plaque by use of optical co-herence tomography.Circulation, 5,1(12):1551-1555.
    [10] Guilbert JJ.The world health report 2002--reducing risks, promoting healthy life.Educ Health (Abingdon), 3,6(2):230.
    [11] Lopez AD, Murray CC.The global burden of disease 1990-2020.Nat Med, 8,4(11):1241-1243.
    [12] Naghavi M, Libby P, Falk E, et al.From vulnerable plaque to vulnerable patient.Circulation, 3,8(14):1664-1672.
    [13] Kamstrup PR, Tybjaerghansen A, Steffensen R, et al.Genetically elevated lipoprotein(a) and increased risk of myocardial infarction.JAMA, 9,1(22):2331-2339.
    [14] Zhou BY, Sun D, Wang C, et al.Plasma lipoprotein(a) concentration is associated with the coronary severity but not with events in stable coronary artery disease patients:A Chinese cohort study.Heart Lung Circ, 2018, DOI:10.1016/j.hlc.2018.05.190.
    [15] Tregouet DA, Konig IR, Erdmann J, et al.Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease.Nat Genet, 9,1(3):283-285.
    [16] Albers JJ, Slee A, O'Brien KD, et al.Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes:the AIM-HIGH trial (atherothrombosis intervention in metabolic syndrome with low HDL/high triglyceride and impact on global health outcomes).J AM Coll Cardiol, 3,2(17):1575-1579.
    [17] Cho JY, Jeong MH, Ahn Y, et al.High lipoprotein(a) levels are associated with long-term adverse outcomes in acute myocardial infarction patients in high Killip classes.Korean Circ J, 0,0(10):491-498.
    [18] Feng Z, Li HL, Bei WJ, et al.Association of lipoprotein(a) with long-term mortality following coronary angiography or percutaneous coronary intervention.Clin Cardiol, 7,0(9):674-678.
    [19] 费玲, 张军, 王长厚, 等.血清脂蛋白(a)水平与血管内超声斑块显像特征的关系.中华临床医师杂志, 4,8(5):888-890.
    [20] 李卫红.冠状动脉硬化易损斑块影响因素与急性冠状动脉综合征的关系.中华临床医师杂志, 3,7(12):169-171.
    [21] 覃群婷, 邓秀婷, 路文盛.脂蛋白(a)的研究进展.中国动脉硬化杂志, 8,6(2):194-200.
    [22] Pepke W, Eisenreich A, Jaster M, et al.Bivalirudin inhibits periprocedural platelet function and tissue factor expression of human smooth muscle cells.Cardiovasc Ther, 3,1(2):115-123.
    [23] Samarghandian S, Borji A, Delkhosh MB, et al.Safranal treatment improves hyperglycemia, hyperlipidemia and oxidative stress in streptozotocin-induced diabetic rats.J Pharm Sci, 3,6(2):352-362.
    [24] Buechler C, Ullrich H, Ritter M, et al.Lipoprotein(a) up-regulates the expression of the plasminogen activator inhibitor 2 in human blood monocytes.Blood, 1,7(4):981-986.
    [25] Leibundgut G, Scipione C, Yin H, et al.Determinants of binding of oxidized phospholipids on apolipoprotein A and lipoprotein(a).J Lipid Res, 3,4(10):815-830.
    [26] 李健斋, 王抒.低密度脂蛋白、脂蛋白(a)与冠心病.中华检验医学杂志, 9,2(1):5-8.
    [27] Niccoli G, Cin D, Scalone G, et al.Lipoprotein(a) is related to coronary atherosclerotic burden and a vulnerable plaque phenotype in angiographically obstructive coronary artery disease.Atherosclerosis, 6,6:214-220.
    引证文献
引用本文

王钧,李幸,贾璐,李晓梅,刘芬,单春方,金思妤,杨毅宁.脂蛋白(a)水平与冠心病患者易损斑块独立相关[J].中国动脉硬化杂志,2019,27(4):293~300.

复制
分享
文章指标
  • 点击次数:853
  • 下载次数: 828
历史
  • 收稿日期:2018-12-19
  • 最后修改日期:2019-01-21
  • 在线发布日期: 2019-04-08